H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data
Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the top long-term biotechnology stocks to buy. On October 14, H.C.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 1,227,590 | $34,065,623 | 0.19% | |
| 2. | RA Capital Management Peter Kolchinsky | 1,020,410 | $28,316,378 | 0.3% | |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,000,000 | $27,750,000 | 1.61% | |
| 4. | Paradigm Biocapital Advisors Senai Asefaw | 665,251 | $18,460,715 | 0.38% | |
| 5. | Parkman Healthcare Partners Greg Martinez | 411,227 | $11,411,549 | +65% | 1.18% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 2,295,920 | $0.00 | 4,505,391 | 2025-08-08 | Filing | |
| $15.61 | 3,202 | $49,997.63 | 3,202 | 2024-12-30 | Filing | |
| $21.37 | 940,499 | $20,098,463.63 | 2,209,471 | 2024-12-19 | Filing | |
| $14.85 | 5,000 | $74,250.00 | 728,113 | 2024-11-25 | Filing | |
| $15.00 | 2,976 | $44,640.00 | 723,113 | 2024-11-25 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.49 | 16 | $439.84 | 11,089 | 2026-03-30 | Filing | |
| $26.65 | 312 | $8,314.86 | 11,105 | 2026-03-30 | Filing | |
| $27.49 | 9 | $247.41 | 37,477 | 2026-03-30 | Filing | |
| $26.65 | 188 | $5,010.24 | 37,486 | 2026-03-30 | Filing | |
| $9.85 | 757 | $7,455.01 | 18,347 | 2025-03-31 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,505,391 | $125,024,600 | 5.9% | |
| 2. | 849,309 | $23,479,147 | 0.01% | |
| 3. | 490,447 | $13,609,904 | 0% | |
| 4. | 296,855 | $8,237,726 | 0.03% | |
| 5. | 202,743 | $5,626,119 | 0% |